What Studies Have NOT Demonstrated in Humans Despite community claims, no controlled human trial has demonstrated: A specific body fat percentage reduction attributable to LR3 IGF-1 cycling A specific lean mass gain figure for the standard 10-day-on / 4-week-off pattern Cardiovascular safety endpoints across repeated cycles Long-term cancer-incidence data for cycled LR3 IGF-1 use Epidemiological data on chronically elevated endogenous IGF-1 has raised theoretical cancer concerns (Yoshida & Delafontaine, 2020), and that concern is one reason community protocols favor short, spaced cycles rather than continuous use
BPC-157 and TB-500 share overlapping cell-migration and tissue-repair pathways, while GHK-Cu is the classic copper-binding tripeptide researched for collagen synthesis and fibroblast biology
Some studies report that even IV GSH may not increase epithelial lining fluid
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
It is fair to say that methylation is almost synonymous with physical function
Menzel J, Jabakhanji A, Biemann R, Mai K, Abraham K, Weikert C
